Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avadomide plus R-CHOP for Poor Risk DLBCL
NCT03283202Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of avadomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Celgene Corporation. Primary endpoints: Maximum Tolerated Dose/Maximum Administered Dose at 18 weeks and Complete Response Rate. Started Oct 2017; status: completed.
02
Drugs
avadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03283202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283202.